InforSense Initiates Annual 'Open House'
News Dec 05, 2005
InforSense Ltd has hosted customers, partners and investors at the company’s London headquarters last week to hear how their integrative analytics platform, InforSense KDE, is providing information-driven insights across a wide variety of industries.
Presenters, including Stephen Calvert, Vice President of Cheminformatics at GlaxoSmithKline and Michael Liebman, Executive Director of the Windber Research Institute, highlighted some of the drug discovery, health care and financial contexts in which InforSense KDE is used as an enterprise environment for business-critical decision-making.
"Many industries face the same challenge of enabling decision-makers to access and use information in a way that keeps pace with changing business needs," said Prof. Yike Guo, CEO and Founder of InforSense.
"InforSense service-oriented workflow technology effectively addresses this challenge by enabling the creation of a single platform to support entire information-driven decision-making processes."
"We see InforSense KDE increasingly adopted by companies in a wide range of sectors as a uniform environment for enterprise-wide decision support."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE